CROI 2025: accepted research projects supported by ANRS MIE
CROI, the international Conference on Retroviruses and Opportunistic Infections, will be held from March 9 to 12 in San Francisco. Around 20 projects supported by ANRS MIE have been accepted.
Last updated on 11 March 2025
In brief
As every year, CROI will highlight the newest and most consequential research in retroviruses and opportunistic infections. 2025 is marked by the presentation of research in SARS-CoV-2 and mpox.
Visit the website of our partner VIH.org* to find articles about the event
*Since 2023, VIH.org and ANRS MIE have been jointly creating content for publication on their respective websites, covering the latest research in HIV/AIDS and emerging infectious diseases. Digital content respects the editorial independence policies of VIH.org and makes it possible to promote the results of research supported by ANRS MIE.
CROI 2025: Research in HIV, opportunistic infections and the consequences of US policies
Discover the talks of Françoise Barré-Sinoussi, 2008 Nobel Prize winner in medicine, and Yazdan Yazdanpanah, director of ANRS MIE.
These testimonies emphasize the key role of the United States in the advancement of research on HIV and infectious diseases. They also address the current and potential impact of US policy changes on research and global health.
Françoise Barré-Sinoussi, Nobel prize winner
Yazdan Yazdanpanah, Director of ANRS MIE
CROI 2025: Oral presentations of research supported by ANRS MIE
- Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells by Clayton Faua et al (Pierre Gantner), Inserm-Université de Strasbourg, France
- Time to Antiretroviral Initiation Among Transgender Women Living with HIV in France (1997-2022) by Juliette Hemery et al (Sophie Grabar), Inserm-Sorbonne université, France
- Genetic mutation differences patterns of Sars-CoV-2 in immunocompromised patients versus controls by Karen Zafilaza et al (Cathia Soulié, Vincent Calvez), Sorbonne université, France
Current antiretroviral molecules prevent the infection of new cells by HIV (pre-integration effect). The first-in-class capsid inhibitor Lenacapavir (LEN) might also display a post-integration effect. For the first time, we show that Lenacapavir does have an effect on the expression of HIV in infected cells. Our in vitro and ex vitro experiments have enabled us to show that, following the LEN-induced degradation of the viral Gag protein, the inhibitor reduces the quantity of viral proteins produced by infected cells. This could have consequences on the size of HIV reservoirs in treated individuals. Our goal is to test the reactivation of infected cells in vivo to eliminate them more effectively (‘shock and kill’ strategy).
The epidemiological context is marked by a high prevalence of HIV among transgender women. Based on longitudinal data from the ANRS CO4 FHDH hospital cohort over the past 20 years, we have shown that since the ‘treat all’ policy in France, delays to initiate antiretroviral treatment for transgender women have been shortened. However, disparities related to geographical origin hinder this implementation. Our future work will aim to compare entering care between transgender women and other key groups such as MSM, cisgender men and cisgender women.
We have shown a greater genetic diversity of the SARS-CoV-2 virus in immunocompromised individuals compared to immunocompetent individuals. This new insight into the evolutionary trajectoriess of the virus paves the way for a better characterization of infections in immunocompromised individuals, ultimately enabling the adaptation of vaccination or therapeutic strategies based on anti-SARS-CoV-2 antibodies. We are conducting an in-depth analysis of the factors that may influence this genetic diversity.
CROI 2025: Posters of accepted projects supported by ANRS MIE
|
Basma Abdi |
No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens |
|
Pantxika Bellecave |
Real-world robustness of B/F/TAF at virologic failure in the ANRS-CO3-AquiVIH-NA cohort |
|
Florence Buseyne |
Negative HIV serology in children treated early reflects a unique immunological profile |
|
Nived Collercandy |
Occult CMV replication is a persistent driver of effector T cell expansion in PWH on effective ART |
|
Nived Collercandy |
Depletion of CX3CR1+ effector CD8 TRM cells is associated with HIV-1 reservoir in the colon on ART |
|
Mathis Collier |
Neurodevelopmental Disorders in French HIV-/ARV-Exposed Uninfected Children: a National Cohort Study |
|
Francesca Di Nunzio |
HIV-1-Membraneless Organelles: Their Role in Viral Genome Maturation and Immune Evasion |
|
Mazouz Fella |
Deciphering the HIV-2 Proviral Reservoir in Antiretroviral-naive Individuals |
|
Nour Gazzhaui |
In vitro and in vivo immunogenicity of a dendritic cell-based vaccine targeting HBV epitopes |
|
Juliette Hemery |
Time to Antiretroviral Initiation Among Transgender Women Living with HIV in France (1997-2022) |
|
Mohamed Joma |
Novel plasma biomarkers for the detection of Long COVID defined by multi-approach analysis |
|
Yves Levy |
Un-adjuvanted CD40.HIVRI.ENV vaccine late boost induces durable immune responses: ANRS/VRI06 trial |
|
Geoffroy Liegeon |
Impact of a HCV test and treat campaign on hepatitis C incidence in the ANRS PREVENIR PREP Study |
|
Amir Mohareb |
Outcomes in HIV-hepatitis B coinfection without tenofovir-containing antiretroviral therapy |
|
Alaric Peyrouny-Mazeau |
Predictive factors of virological failure after switching to B/F/TAF (ANRS-CO3-AquiVIH-NA) |
|
Luis Sagaon Teyssier |
Community-based versus facility-based services to improve HIV care in the gold mining zones of Mali |
|
Rachelle Saleh |
Variability in immunometabolic signatures among HIV patients defines immune outcomes and progression |
|
Cathia Soulié |
Despite Increasing Use of INIs To Treat HIV Infection, Resistance To This Class Remains Stable |
|
Karen Zafilaza |
Genetic mutation differences patterns of Sars-CoV-2 in immunocompromised patients versus controls |
Find the abstracts on the CROI website.